Compounds > daunorubicin
Page last updated: 2024-08-23

daunorubicin and quizartinib

daunorubicin has been researched along with quizartinib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
He, R; Li, J; Liu, X; Pan, R; Wang, C1

Other Studies

2 other study(ies) available for daunorubicin and quizartinib

ArticleYear
Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
    Biochemical and biophysical research communications, 2019, 09-24, Volume: 517, Issue:3

    Topics: Anilides; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzothiazoles; Bone Density Conservation Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Child; Cytarabine; Daunorubicin; Drug Repositioning; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Pamidronate; Phenylurea Compounds; Primary Cell Culture; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; ras Proteins

2019
Quizartinib (Vanflyta) for acute myeloid leukemia.
    The Medical letter on drugs and therapeutics, 2023, 10-16, Volume: 65, Issue:1687

    Topics: Benzothiazoles; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Phenylurea Compounds

2023